FDA Approves Enhertu for Two New Early HER2+ Breast Cancer Indications

summarizeSummary

AstraZeneca and Daiichi Sankyo's Enhertu has received US FDA approval for two new indications in HER2-positive early breast cancer, expanding its use into neoadjuvant and adjuvant settings.

check_boxKey Events

• FDA Approval for Early Breast Cancer

  Enhertu (trastuzumab deruxtecan) has been approved by the US FDA for two new indications in HER2-positive early breast cancer: neoadjuvant (before surgery) and adjuvant (following surgery).

• Strong Clinical Efficacy

  In the neoadjuvant setting (DESTINY-Breast11), Enhertu showed an 11.2% improvement in pathologic complete response (pCR) rate. In the adjuvant setting (DESTINY-Breast05), it reduced the risk of invasive disease recurrence or death by 53%.

• Expanded Market Opportunity

  These approvals bring Enhertu into curative-intent settings, reinforcing its role across stages of HER2-positive breast cancer and expanding its market potential.

• Milestone Payment to Daiichi Sankyo

  AstraZeneca will pay Daiichi Sankyo $155 million in milestone payments for these two indications, as sales of Enhertu in the US are recognized by Daiichi Sankyo.

auto_awesomeAnalysis

The US FDA approval of Enhertu for use before and after surgery in HER2-positive early breast cancer significantly expands the drug's market potential into curative-intent settings. This approval is based on strong Phase III data showing improved pathologic complete response rates and a substantial reduction in disease recurrence, reinforcing Enhertu's role as a foundational treatment and offering new hope for patients at risk of recurrence.